S&P 500
(0.11%) 5 254.35 points
Dow J
(0.12%) 39 807 points
Nasdaq
(-0.12%) 16 379 points
Oil
(-0.07%) $83.11
Gas
(-0.62%) $1.752
Gold
(0.73%) $2 254.80
Silver
(0.74%) $25.10
Platinum
(0.21%) $923.00
USD/EUR
(0.03%) $0.927
USD/NOK
(0.11%) $10.85
USD/GBP
(-0.13%) $0.791
USD/RUB
(-0.24%) $92.35

Sanntidsoppdatering for Annexon, Inc. [ANNX]

Børs: NASDAQ Sektor: Healthcare Industri: Biotechnology
Upcoming Earnings Alert

3 days till quarter result
(bmo 2024-04-01)

Expected move: +/- 8.09%

BUY
71.43%
return 21.99%
SELL
42.86%
return 6.38%
Sist oppdatert28 mar 2024 @ 21:00

-8.19% $ 7.17

KJøP 63105 min ago

@ $5.26

Utstedt: 14 feb 2024 @ 20:48


Avkastning: 36.44%


Forrige signal: feb 14 - 15:31


Forrige signal: Selg


Avkastning: 2.24 %

Live Chart Being Loaded With Signals

Commentary (28 mar 2024 @ 21:00):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders...

Stats
Dagens volum 3.81M
Gjennomsnittsvolum 1.48M
Markedsverdi 561.68M
EPS $-0.430 ( 2023-11-13 )
Neste inntjeningsdato ( $-0.450 ) 2024-04-01
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -3.96
ATR14 $0.0170 (0.24%)
Insider Trading
Date Person Action Amount type
2024-02-16 Love Douglas Buy 656 200 Stock Option (Right to Buy)
2024-02-16 Dananberg Jamie Buy 160 000 Stock Option (Right to Buy)
2024-02-16 Dananberg Jamie Buy 39 000 Common Stock
2024-02-16 Artis Dean Richard Buy 160 000 Stock Option (Right to Buy)
2024-02-16 Artis Dean Richard Buy 39 000 Common Stock
INSIDER POWER
80.81
Last 94 transactions
Buy: 9 115 180 | Sell: 879 119

Volum Korrelasjon

Lang: -0.27 (neutral)
Kort: 0.35 (neutral)
Signal:(62.85) Neutral

Annexon, Inc. Korrelasjon

10 Mest positive korrelasjoner
RMRM0.934
GTHX0.93
STKL0.913
NUTX0.91
EYE0.91
DXCM0.91
SDG0.909
EAR0.908
SVOK0.907
RRGB0.906
10 Mest negative korrelasjoner
HDSN-0.916
LCA-0.9
MDWT-0.896
NVCN-0.89
SENEA-0.885
OHAA-0.882
HNRG-0.879
ROKU-0.878
IGTA-0.877
FCBP-0.877

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Annexon, Inc. Korrelasjon - Valuta/Råvare

The country flag -0.32
( neutral )
The country flag 0.50
( neutral )
The country flag 0.00
( neutral )
The country flag 0.33
( neutral )
The country flag 0.59
( weak )
The country flag -0.13
( neutral )

Annexon, Inc. Økonomi

Annual 2023
Omsetning: $0
Bruttogevinst: $-3.27M (0.00 %)
EPS: $-1.770
Q4 2023
Omsetning: $0
Bruttogevinst: $-834 000 (0.00 %)
EPS: $-0.360
Q3 2023
Omsetning: $0
Bruttogevinst: $-823 000 (0.00 %)
EPS: $-0.430
Q2 2023
Omsetning: $0
Bruttogevinst: $-810 000 (0.00 %)
EPS: $-0.470

Financial Reports:

No articles found.

Annexon, Inc.

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Om Live Signaler

Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.

Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.